Chronic Kidney Disease (CKD) Drugs Market Size Worth US$ 19.8 billion by 2030 – Growth Plus Reports
Newark, New Castle, USA, March 16, 2023 (GLOBE NEWSWIRE) — According to the deep-dive market assessment study by Growth Plus Reports, the global chronic kidney disease (CKD) drugs market was valued at US$ 13.2 billion in 2021 and is expected to register a revenue CAGR of 5.2% to reach US$ 19.8 billion by 2030.
Chronic kidney disease (CKD) causes the body to lose kidney function, leading to kidney failure gradually. Chronic kidney disorders harm renal function by accumulating a high quantity of fluid, electrolytes, and wastes in the body. Anorexia, loss of appetite, trouble sleeping, vomiting, itchiness, exhaustion, weakness, high blood pressure, shortness of breath, chest pain, and other symptoms are some of the signs and symptoms of chronic kidney disease. With time, these symptoms worsen and may eventually cause end-stage kidney failure, necessitating either dialysis or a kidney transplant for the patient.
Request Free Sample Copy of the Research Report: https://www.growthplusreports.com/inquiry/request-sample/chronic-kidney-disease-ckd-drugs-market/8272
Chronic Kidney Disease (CKD) Drugs Market Scope
| Report Attribute | Details |
| Market size value in 2021 | US$ 13.2 billion |
| Revenue forecast in 2030 | US$ 19.8 billion |
| Growth Rate | CAGR of 5.2% from 2022 to 2030 |
| Base year for estimation | 2021 |
| Forecast period | 2022-2030 |
| Historical Year | 2020 |
| Segments covered | Drug Class, Route of Administration, End-user, and Region. |
| Regional scope | North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
Market Drivers
Major reasons, including the rising prevalence of chronic kidney disease among patients worldwide, fuel the global chronic kidney disease market growth. The desire for novel treatments to enhance patients’ quality of life is rising as the prevalence of chronic renal disease rises. The number of Americans with chronic kidney disease is anticipated to be over 37 million, according to a report released by the Centers for Disease Control and Prevention in 2019. Also, the market is primarily driven by the growing elderly population because this group of people over 60 is more likely to have chronic renal disorders than younger people. Thus, increased research and development efforts in creating medications for the chronic renal disease are projected to fuel the market expansion. Yet, significant obstacles are preventing the global market for drugs to treat chronic kidney disease from expanding. The global market faces significant challenges, including the growing penetration of generic medications. Also, a lack of patient compliance in some nations is anticipated to restrain the expansion of the global market for drugs treating chronic kidney disease.
The global chronic kidney disease (CKD) drugs market is analyzed from four perspectives: Drug Class, Route of Administration, End-user, and Region.
Excerpts from ‘By Drug Class Segmentation’
Based on the drug classes, the global chronic kidney diseases market is segmented into:
- ACE Inhibitors
- Angiotensin-II Receptor Blockers
- Beta-Blockers
- Calcium Channel Blockers
- Diuretics
- Erythropoiesis-Stimulating Agents (Esas)
- Others
The calcium channel blockers segment accounted for the largest revenue share for the global chronic kidney disease drugs market in 2021. Calcium channel blockers are utilized to treat hypertension. They function by keeping calcium out of the arteries and heart cells. Drugs that inhibit calcium channel blockers (CCBs) are among the potential antihypertensive drug classes currently available for chronic kidney disease clinical management. They effectively and safely reduce high blood pressure and accomplish the recommended blood pressure benchmarks with a good tolerability profile. Over time, calcium channel blockers have become one of the most popular groups of antihypertensive drugs due to their efficiency in regulating blood pressure levels, good tolerability, and solid evidence of lessening the cardiovascular and renal effects of hypertension.
Excerpts from ‘By Region Segmentation’
Based on the region, the global chronic kidney disease drugs market is segmented into:
- North America
- Europe
- Asia Pacific
- Rest of the World
North America accounted for the largest revenue share of the global chronic kidney disease drugs market in 2021. During the forecast period, North America is anticipated to hold a major market share for chronic kidney disorders. Rising rates of chronic renal disease, a developed healthcare system, high health spending, and technologically sophisticated diagnostic procedures are the main drivers of market expansion. The primary driver fueling market growth is the rising prevalence of chronic renal disorders in the population. For instance, the American Kidney Fund reported in February 2022 that an estimated 37 million people suffer from kidney disease.
The region of Asia-Pacific is anticipated to witness the fastest revenue growth for the global chronic kidney disease drugs market owing to an increase in the accessibility of healthcare facilities and treatments, a rise in kidney disease rates, an intensification in governmental and private sector investment in the pharmaceutical industry, and the entry of international companies.
Request for Customization – https://www.growthplusreports.com/inquiry/customization/chronic-kidney-disease-ckd-drugs-market/8272
Excerpts from ‘Competitive Landscape’
Key companies operating the global chronic kidney disease drugs market are:
- AstraZeneca plc.
- Pfizer Inc.
- Amgen Inc.
- FibroGen, Inc.
- GlaxoSmithKline plc.
- F. Hoffmann-La Roche
- AbbVie Inc.
- Akebia Therapeutics, Inc.
- Teva Pharmaceutical Industries Ltd.
- Johnson & Johnson Services, Inc.
- Sanofi SA
- Regeneron Pharmaceuticals, Inc.
- Kissei Pharmaceutical Co., Ltd.
- Reata Pharmaceuticals, Inc.
- Ardelyx, Inc.
- Novo Nordisk AS
- Novartis AG
- Takeda Pharmaceutical Company Limited
Table of Content
- INTRODUCTION
- Market Ecosystem
- Timeline Under Consideration
- Historical Years – 2020
- Base Year – 2021
- Forecast Years – 2022 to 2030
- Currency Used in the Report
- RESEARCH METHODOLOGY
- Research Approach
- Data Collection Methodology
- Data Sources
- Secondary Sources
- Primary Sources
- Market Estimation Approach
- Bottom Up
- Top Down
- Market Forecasting Model
- Limitations and Assumptions
- PREMIUM INSIGHTS
- Current Market Trends (COVID-19 Perspective)
- Key Players & Competitive Positioning (2021)
- MARKET DYNAMICS
- Drivers
- Restraints/Challenges
- Opportunities
- GLOBAL CHRONIC KIDNEY DISEASE (CKD) DRUGS MARKET – ANALYSIS & FORECAST, BY DRUG CLASS
- ACE Inhibitors
- Angiotensin-II Receptor Blockers
- Beta-Blockers
- Calcium Channel Blockers
- Diuretics
- Erythropoiesis-Stimulating Agents (ESAs)
- Others
TOC Continued…
Buy this Premium Research Report: https://www.growthplusreports.com/checkout-8272
VALUE PROPOSITIONS RELATED TO THE REPORT:
- Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
- Comprehensive quantitative and qualitative insights at segment and sub-segment level
- Covid 19 impact trends and perspective
- Granular insights at global/regional/country level
- Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
- Blanket coverage on competitive landscape
- Winning imperatives
- Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market
CUSTOMIZATION OPTIONS:
- Distributor Landscape Assessment
- Pricing Intelligence
- Customer Base Assessment
- Investment & Initiatives Analysis
- ‘Business Profile’ of Key Players
Schedule a call with our analyst: https://appoint.ly/s/salesZ3Jvd3RocGx1c3JlcG9ydHMuY29t/introduction
Visit our report store at – https://www.growthplusreports.com/report-store
Browse related reports:
Felty Syndrome Market by Drug Class (Immunosuppressants, TNF-Inhibitors), Route of Administration (Oral, Topical, Parental), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Global Outlook & Forecast 2023-2031
mRNA Therapeutics Market by Type (Prophylactic Vaccine, Therapeutic drugs), Application (Rare Genetic Diseases, Infectious Diseases), End User (Hospitals & Clinics, Research Organizations) – Global Outlook and Forecast 2023-2031
Health Kiosk Market by Type (Check-In Kiosk, Payment Kiosk), Location (Hospitals, Specialty Clinics) – Global Outlook & Forecast 2023-2031
Dermatology Supplements Market by Product (Vitamin, Collagen), Distribution Channel (Online, Offline) – Global Outlook and Forecast 2023-2031
Companion Animal Genetic Testing Market by Animal Type (Dogs, Cats), Sample Type (Blood, Saliva), Test Type (Breed Profile, Genetic Diseases) – Global Outlook & Forecast 2023-2031
About Us:
Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).
Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.
We were awarded by the prestigious CEO Magazine as “Most Innovative Healthcare Market Research Company in 2020.
CONTACT: Manan Sethi Director, Market Insights Email: [email protected] 256 Chapman Road STE 105-4, Newark, New Castle - 19702, USA Phone no: +1 888 550 5009 Web: https://www.growthplusreports.com/
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. NewIndiaObserver.com takes no editorial responsibility for the same.